PMS37 Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan

Simple item page
dc.contributor.authorBektur, C.
dc.contributor.authorKayir, F.
dc.contributor.authorNurgozhin, T.
dc.creatorC., Bektur
dc.date.accessioned2017-12-13T04:46:26Z
dc.date.available2017-12-13T04:46:26Z
dc.date.issued2014-11-01
dc.description.abstractThe purpose of present study was to evaluate the cost-effectiveness of tocilizumab (TCZ) vs. infliximab (IFX) for the treatment of patients with rheumatoid arthritis (RA) from the perspective of Ministry of Health (MoH) over a patient lifetime horizon in Kazakhstan.en_US
dc.identifierDOI:10.1016/j.jval.2014.08.2607
dc.identifier.citationC. Bektur, F. Kayir, T. Nurgozhin, PMS37 - Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstan, In Value in Health, Volume 17, Issue 7, 2014, Page A379en_US
dc.identifier.issn10983015
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S1098301514045562
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/2860
dc.language.isoenen_US
dc.publisherValue in Healthen_US
dc.relation.ispartofValue in Health
dc.rightsOpen Access - the content is available to the general publicen_US
dc.rights.licenseCopyright © 2014 Published by Elsevier Inc.
dc.titlePMS37 Cost-Effectiveness Analysis of Tocilizumab Verse Infliximab for the Patients With Rheumatoid Arthritis in Kazakhstanen_US
dc.typeArticleen_US
elsevier.aggregationtypeJournal
elsevier.coverdate2014-11-01
elsevier.coverdisplaydateNovember 2014
elsevier.identifier.doi10.1016/j.jval.2014.08.2607
elsevier.identifier.eid1-s2.0-S1098301514045562
elsevier.identifier.piiS1098-3015(14)04556-2
elsevier.issue.identifier7
elsevier.openaccess1
elsevier.openaccessarticletrue
elsevier.openaccessuserlicensehttp://www.elsevier.com/open-access/userlicense/1.0/
elsevier.openarchivearticletrue
elsevier.startingpageA379
elsevier.volume17
workflow.import.sourcescience

Files

Collections

Articles